Achieve Life Sciences to present 52-week cytisinicline data at CHEST 2026

ACHV•2026-09-28

Achieve Life Sciences plans to present 52-week cytisinicline efficacy data from its open-label ORCA-OL smoking and e-cigarette cessation trial on Oct. 20, 2026; the study enrolled 475 adults who continued to smoke or vape daily after earlier cytisinicline studies.

Achieve Life Sciences to present 52-week cytisinicline data at CHEST 2026

1. Trial data presentation

Related News

Palisade Bio says Phase 1b study shows early gains for PALI-2108 in Crohn’s disease

RideNow Group secures $220 million senior secured term loan from Centerbridge affiliates

Cerebras to supply AI systems to cloud computing startup Gimlet Labs

DLH wins NIH cybersecurity operations task order worth up to $19.1 million

Nasdaq trading halt continues, reason unavailable at 9:00 a.m.